{"id":"W4401305294","doi":"10.1016/j.annonc.2024.07.727","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Genentech; Astellas Pharma; Eisai; European Society for Medical Oncology; European Association of Urology; Seagen; Advanced Accelerator Applications; National Institutes of Health; CVS Health; Amgen; Deciphera Pharmaceuticals; Jounce Therapeutics; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; Merck KGaA; Endocyte; Nihon Pharmaceutical; PTC Therapeutics; BioCryst; Ipsen; Array BioPharma; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Gilead Sciences; Revolution Medicines; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; EUSA Pharma; AstraZeneca; American Society of Clinical Oncology; Coherus Biosciences; Arrowhead Pharmaceuticals; GlaxoSmithKline; Dana-Farber Cancer Institute; Incyte; Pfizer","keywords":"Medicine; Sunitinib; Ipilimumab; Nivolumab; Renal cell carcinoma; Internal medicine; Oncology; Urology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004131095,0.0003203666,0.001272729,0.0001351166,0.00007685626,0.000006868086,0.0001435024,0.0002068654,0.00005317498],"category_scores_gemma":[0.0002753168,0.0002173448,0.0004340228,0.0002002962,0.000292623,0.00005575005,0.00006138807,0.0001274554,0.000003272761],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002171684,"about_ca_system_score_gemma":0.0006294869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005541436,"about_ca_topic_score_gemma":0.0002510567,"domain_scores_codex":[0.9975674,0.0001575351,0.001114848,0.0005146683,0.0002803251,0.0003652306],"domain_scores_gemma":[0.9957162,0.002775998,0.0004657057,0.0005792642,0.0003078813,0.0001549708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8905522,0.003073503,0.00001135455,0.0002194649,0.0007690537,0.000153157,0.002994744,0.00005174478,0.01033471,0.0001084737,0.001258595,0.09047296],"study_design_scores_gemma":[0.6892043,0.123879,0.00105936,0.0001698409,0.001437374,0.00001322384,0.0006758595,0.0003279384,0.1584795,0.0001089907,0.02447104,0.0001735629],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864795,0.004695525,0.00002764423,0.001937297,0.0007088371,0.002604613,0.001329718,0.00002839173,0.002188499],"genre_scores_gemma":[0.996089,0.001548398,0.0005046114,0.00003217725,0.000335157,0.0001326543,0.0006321923,0.00003988686,0.000685944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.201348,"threshold_uncertainty_score":0.8863064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1106144697575583,"score_gpt":0.3866629650592868,"score_spread":0.2760484953017285,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}